CN114250203B - 一种鼠抗mcr-1/mcr-2蛋白杂交瘤细胞株,单克隆抗体及应用 - Google Patents
一种鼠抗mcr-1/mcr-2蛋白杂交瘤细胞株,单克隆抗体及应用 Download PDFInfo
- Publication number
- CN114250203B CN114250203B CN202210189230.1A CN202210189230A CN114250203B CN 114250203 B CN114250203 B CN 114250203B CN 202210189230 A CN202210189230 A CN 202210189230A CN 114250203 B CN114250203 B CN 114250203B
- Authority
- CN
- China
- Prior art keywords
- mcr
- antibody
- seq
- protein
- variable region
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 108700012262 E coli mcr-2 Proteins 0.000 title claims abstract description 66
- 210000004408 hybridoma Anatomy 0.000 title claims abstract description 27
- 238000000034 method Methods 0.000 claims abstract description 18
- 239000003153 chemical reaction reagent Substances 0.000 claims abstract description 10
- 238000003745 diagnosis Methods 0.000 claims abstract description 8
- 238000000338 in vitro Methods 0.000 claims abstract description 7
- 101150004219 MCR1 gene Proteins 0.000 claims description 27
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical group [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 claims description 25
- 238000004321 preservation Methods 0.000 claims description 22
- 239000011248 coating agent Substances 0.000 claims description 14
- 238000000576 coating method Methods 0.000 claims description 14
- 239000002773 nucleotide Substances 0.000 claims description 14
- 125000003729 nucleotide group Chemical group 0.000 claims description 14
- 241001529936 Murinae Species 0.000 claims description 11
- 108020004707 nucleic acids Proteins 0.000 claims description 11
- 102000039446 nucleic acids Human genes 0.000 claims description 11
- 150000007523 nucleic acids Chemical class 0.000 claims description 11
- 238000002360 preparation method Methods 0.000 claims description 8
- 238000003018 immunoassay Methods 0.000 claims description 6
- 238000012360 testing method Methods 0.000 claims description 6
- 238000008157 ELISA kit Methods 0.000 claims description 3
- 238000003127 radioimmunoassay Methods 0.000 claims description 3
- 125000003275 alpha amino acid group Chemical group 0.000 claims 4
- 239000003814 drug Substances 0.000 abstract description 11
- 108010040201 Polymyxins Proteins 0.000 abstract description 10
- 229940079593 drug Drugs 0.000 abstract description 10
- 238000011156 evaluation Methods 0.000 abstract description 5
- 230000009897 systematic effect Effects 0.000 abstract description 3
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 abstract description 2
- 238000003757 reverse transcription PCR Methods 0.000 abstract description 2
- 238000012216 screening Methods 0.000 abstract 1
- 230000003248 secreting effect Effects 0.000 abstract 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 30
- 210000004027 cell Anatomy 0.000 description 30
- 239000000243 solution Substances 0.000 description 20
- 239000000523 sample Substances 0.000 description 11
- 241000699670 Mus sp. Species 0.000 description 10
- UQLDLKMNUJERMK-UHFFFAOYSA-L di(octadecanoyloxy)lead Chemical compound [Pb+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O UQLDLKMNUJERMK-UHFFFAOYSA-L 0.000 description 10
- 238000007865 diluting Methods 0.000 description 9
- 150000001413 amino acids Chemical group 0.000 description 8
- 239000000427 antigen Substances 0.000 description 8
- 102000036639 antigens Human genes 0.000 description 8
- 108091007433 antigens Proteins 0.000 description 8
- 238000001514 detection method Methods 0.000 description 8
- 238000005406 washing Methods 0.000 description 8
- 206010003445 Ascites Diseases 0.000 description 7
- 238000007710 freezing Methods 0.000 description 7
- 230000008014 freezing Effects 0.000 description 7
- 239000008055 phosphate buffer solution Substances 0.000 description 7
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- 206010059866 Drug resistance Diseases 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 238000001035 drying Methods 0.000 description 6
- 230000003053 immunization Effects 0.000 description 6
- 238000002156 mixing Methods 0.000 description 6
- 239000013612 plasmid Substances 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 108010077245 asparaginyl-proline Proteins 0.000 description 5
- 238000002649 immunization Methods 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 210000004988 splenocyte Anatomy 0.000 description 5
- 239000006228 supernatant Substances 0.000 description 5
- 241000894006 Bacteria Species 0.000 description 4
- 108020004414 DNA Proteins 0.000 description 4
- 238000002965 ELISA Methods 0.000 description 4
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 4
- 210000000683 abdominal cavity Anatomy 0.000 description 4
- 239000002671 adjuvant Substances 0.000 description 4
- 239000012620 biological material Substances 0.000 description 4
- 238000010367 cloning Methods 0.000 description 4
- 239000002299 complementary DNA Substances 0.000 description 4
- 238000012258 culturing Methods 0.000 description 4
- 230000004927 fusion Effects 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 238000009629 microbiological culture Methods 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 238000002331 protein detection Methods 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 210000000952 spleen Anatomy 0.000 description 4
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- 241000283707 Capra Species 0.000 description 3
- 239000012980 RPMI-1640 medium Substances 0.000 description 3
- CDHQEOXPWBDFPL-QWRGUYRKSA-N Tyr-Gly-Asn Chemical compound NC(=O)C[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H](N)CC1=CC=C(O)C=C1 CDHQEOXPWBDFPL-QWRGUYRKSA-N 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 239000012496 blank sample Substances 0.000 description 3
- 238000007664 blowing Methods 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 238000001962 electrophoresis Methods 0.000 description 3
- 239000003292 glue Substances 0.000 description 3
- XBGGUPMXALFZOT-UHFFFAOYSA-N glycyl-L-tyrosine hemihydrate Natural products NCC(=O)NC(C(O)=O)CC1=CC=C(O)C=C1 XBGGUPMXALFZOT-UHFFFAOYSA-N 0.000 description 3
- XKUKSGPZAADMRA-UHFFFAOYSA-N glycyl-glycyl-glycine Chemical compound NCC(=O)NCC(=O)NCC(O)=O XKUKSGPZAADMRA-UHFFFAOYSA-N 0.000 description 3
- 108010089804 glycyl-threonine Proteins 0.000 description 3
- 108010050848 glycylleucine Proteins 0.000 description 3
- 108010051242 phenylalanylserine Proteins 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 238000011144 upstream manufacturing Methods 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- HUZGPXBILPMCHM-IHRRRGAJSA-N Asn-Arg-Phe Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O HUZGPXBILPMCHM-IHRRRGAJSA-N 0.000 description 2
- RTFXPCYMDYBZNQ-SRVKXCTJSA-N Asn-Tyr-Asn Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(N)=O)C(O)=O RTFXPCYMDYBZNQ-SRVKXCTJSA-N 0.000 description 2
- DTNUIAJCPRMNBT-WHFBIAKZSA-N Asp-Gly-Ala Chemical compound [H]N[C@@H](CC(O)=O)C(=O)NCC(=O)N[C@@H](C)C(O)=O DTNUIAJCPRMNBT-WHFBIAKZSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 235000009161 Espostoa lanata Nutrition 0.000 description 2
- 240000001624 Espostoa lanata Species 0.000 description 2
- MFNUFCFRAZPJFW-JYJNAYRXSA-N Glu-Lys-Phe Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 MFNUFCFRAZPJFW-JYJNAYRXSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- YQFZRHYZLARWDY-IHRRRGAJSA-N Leu-Val-Lys Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(O)=O)CCCCN YQFZRHYZLARWDY-IHRRRGAJSA-N 0.000 description 2
- GILLQRYAWOMHED-DCAQKATOSA-N Lys-Val-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](N)CCCCN GILLQRYAWOMHED-DCAQKATOSA-N 0.000 description 2
- SPSSJSICDYYTQN-HJGDQZAQSA-N Met-Thr-Gln Chemical compound CSCC[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@H](C(O)=O)CCC(N)=O SPSSJSICDYYTQN-HJGDQZAQSA-N 0.000 description 2
- YBAFDPFAUTYYRW-UHFFFAOYSA-N N-L-alpha-glutamyl-L-leucine Natural products CC(C)CC(C(O)=O)NC(=O)C(N)CCC(O)=O YBAFDPFAUTYYRW-UHFFFAOYSA-N 0.000 description 2
- SUHOOTKUPISOBE-UHFFFAOYSA-N O-phosphoethanolamine Chemical compound NCCOP(O)(O)=O SUHOOTKUPISOBE-UHFFFAOYSA-N 0.000 description 2
- NOXSEHJOXCWRHK-DCAQKATOSA-N Pro-Cys-Leu Chemical compound CC(C)C[C@@H](C(=O)O)NC(=O)[C@H](CS)NC(=O)[C@@H]1CCCN1 NOXSEHJOXCWRHK-DCAQKATOSA-N 0.000 description 2
- VBZXFFYOBDLLFE-HSHDSVGOSA-N Pro-Trp-Thr Chemical compound N([C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H]([C@H](O)C)C(O)=O)C(=O)[C@@H]1CCCN1 VBZXFFYOBDLLFE-HSHDSVGOSA-N 0.000 description 2
- QHSSUIHLAIWXEE-IHRRRGAJSA-N Pro-Tyr-Asn Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(N)=O)C(O)=O QHSSUIHLAIWXEE-IHRRRGAJSA-N 0.000 description 2
- UIGMAMGZOJVTDN-WHFBIAKZSA-N Ser-Gly-Ser Chemical compound OC[C@H](N)C(=O)NCC(=O)N[C@@H](CO)C(O)=O UIGMAMGZOJVTDN-WHFBIAKZSA-N 0.000 description 2
- ZUDXUJSYCCNZQJ-DCAQKATOSA-N Ser-His-Val Chemical compound CC(C)[C@@H](C(=O)O)NC(=O)[C@H](CC1=CN=CN1)NC(=O)[C@H](CO)N ZUDXUJSYCCNZQJ-DCAQKATOSA-N 0.000 description 2
- SIEBDTCABMZCLF-XGEHTFHBSA-N Ser-Val-Thr Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O SIEBDTCABMZCLF-XGEHTFHBSA-N 0.000 description 2
- BGFCXQXETBDEHP-BZSNNMDCSA-N Tyr-Phe-Asn Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(N)=O)C(O)=O BGFCXQXETBDEHP-BZSNNMDCSA-N 0.000 description 2
- ANHVRCNNGJMJNG-BZSNNMDCSA-N Tyr-Tyr-Cys Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)N[C@@H](CC2=CC=C(C=C2)O)C(=O)N[C@@H](CS)C(=O)O)N)O ANHVRCNNGJMJNG-BZSNNMDCSA-N 0.000 description 2
- ZRSZTKTVPNSUNA-IHRRRGAJSA-N Val-Lys-Leu Chemical compound CC(C)C[C@H](NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)C(C)C)C(O)=O ZRSZTKTVPNSUNA-IHRRRGAJSA-N 0.000 description 2
- 210000001015 abdomen Anatomy 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 108010068265 aspartyltyrosine Proteins 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 210000005252 bulbus oculi Anatomy 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 108010037850 glycylvaline Proteins 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- 108010057952 lysyl-phenylalanyl-lysine Proteins 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 229910052759 nickel Inorganic materials 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 108010070409 phenylalanyl-glycyl-glycine Proteins 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000003908 quality control method Methods 0.000 description 2
- 238000007789 sealing Methods 0.000 description 2
- 235000020183 skimmed milk Nutrition 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 230000007480 spreading Effects 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 2
- 229940033663 thimerosal Drugs 0.000 description 2
- 239000011534 wash buffer Substances 0.000 description 2
- REAQAWSENITKJL-DDWPSWQVSA-N Ala-Met-Asp-Tyr Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O REAQAWSENITKJL-DDWPSWQVSA-N 0.000 description 1
- RTZCUEHYUQZIDE-WHFBIAKZSA-N Ala-Ser-Gly Chemical compound C[C@H](N)C(=O)N[C@@H](CO)C(=O)NCC(O)=O RTZCUEHYUQZIDE-WHFBIAKZSA-N 0.000 description 1
- HOVPGJUNRLMIOZ-CIUDSAMLSA-N Ala-Ser-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](C)N HOVPGJUNRLMIOZ-CIUDSAMLSA-N 0.000 description 1
- CREYEAPXISDKSB-FQPOAREZSA-N Ala-Thr-Tyr Chemical compound [H]N[C@@H](C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O CREYEAPXISDKSB-FQPOAREZSA-N 0.000 description 1
- XMIAMUXIMWREBJ-HERUPUMHSA-N Ala-Trp-Asn Chemical compound C[C@@H](C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)N[C@@H](CC(=O)N)C(=O)O)N XMIAMUXIMWREBJ-HERUPUMHSA-N 0.000 description 1
- OMSKGWFGWCQFBD-KZVJFYERSA-N Ala-Val-Thr Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O OMSKGWFGWCQFBD-KZVJFYERSA-N 0.000 description 1
- GIVATXIGCXFQQA-FXQIFTODSA-N Arg-Ala-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CCCN=C(N)N GIVATXIGCXFQQA-FXQIFTODSA-N 0.000 description 1
- VWVPYNGMOCSSGK-GUBZILKMSA-N Arg-Arg-Asn Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(O)=O VWVPYNGMOCSSGK-GUBZILKMSA-N 0.000 description 1
- KWTVWJPNHAOREN-IHRRRGAJSA-N Arg-Asn-Phe Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O KWTVWJPNHAOREN-IHRRRGAJSA-N 0.000 description 1
- YSUVMPICYVWRBX-VEVYYDQMSA-N Arg-Asp-Thr Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O YSUVMPICYVWRBX-VEVYYDQMSA-N 0.000 description 1
- ZATRYQNPUHGXCU-DTWKUNHWSA-N Arg-Gly-Pro Chemical compound C1C[C@@H](N(C1)C(=O)CNC(=O)[C@H](CCCN=C(N)N)N)C(=O)O ZATRYQNPUHGXCU-DTWKUNHWSA-N 0.000 description 1
- WMEVEPXNCMKNGH-IHRRRGAJSA-N Arg-Leu-His Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)NC(=O)[C@H](CCCN=C(N)N)N WMEVEPXNCMKNGH-IHRRRGAJSA-N 0.000 description 1
- AOHKLEBWKMKITA-IHRRRGAJSA-N Arg-Phe-Ser Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CO)C(=O)O)NC(=O)[C@H](CCCN=C(N)N)N AOHKLEBWKMKITA-IHRRRGAJSA-N 0.000 description 1
- FRBAHXABMQXSJQ-FXQIFTODSA-N Arg-Ser-Ser Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(O)=O FRBAHXABMQXSJQ-FXQIFTODSA-N 0.000 description 1
- WCZXPVPHUMYLMS-VEVYYDQMSA-N Arg-Thr-Asp Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(O)=O WCZXPVPHUMYLMS-VEVYYDQMSA-N 0.000 description 1
- BVLIJXXSXBUGEC-SRVKXCTJSA-N Asn-Asn-Tyr Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O BVLIJXXSXBUGEC-SRVKXCTJSA-N 0.000 description 1
- HDHZCEDPLTVHFZ-GUBZILKMSA-N Asn-Leu-Glu Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O HDHZCEDPLTVHFZ-GUBZILKMSA-N 0.000 description 1
- FTNRWCPWDWRPAV-BZSNNMDCSA-N Asn-Phe-Phe Chemical compound C([C@H](NC(=O)[C@H](CC(N)=O)N)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 FTNRWCPWDWRPAV-BZSNNMDCSA-N 0.000 description 1
- MRQQMVZUHXUPEV-IHRRRGAJSA-N Asp-Arg-Phe Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O MRQQMVZUHXUPEV-IHRRRGAJSA-N 0.000 description 1
- XYBJLTKSGFBLCS-QXEWZRGKSA-N Asp-Arg-Val Chemical compound NC(N)=NCCC[C@@H](C(=O)N[C@@H](C(C)C)C(O)=O)NC(=O)[C@@H](N)CC(O)=O XYBJLTKSGFBLCS-QXEWZRGKSA-N 0.000 description 1
- NYQHSUGFEWDWPD-ACZMJKKPSA-N Asp-Gln-Ala Chemical compound C[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CC(=O)O)N NYQHSUGFEWDWPD-ACZMJKKPSA-N 0.000 description 1
- QNFRBNZGVVKBNJ-PEFMBERDSA-N Asp-Ile-Gln Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)[C@H](CC(=O)O)N QNFRBNZGVVKBNJ-PEFMBERDSA-N 0.000 description 1
- YFSLJHLQOALGSY-ZPFDUUQYSA-N Asp-Ile-Lys Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CC(=O)O)N YFSLJHLQOALGSY-ZPFDUUQYSA-N 0.000 description 1
- AYFVRYXNDHBECD-YUMQZZPRSA-N Asp-Leu-Gly Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(O)=O AYFVRYXNDHBECD-YUMQZZPRSA-N 0.000 description 1
- UMHUHHJMEXNSIV-CIUDSAMLSA-N Asp-Leu-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CC(O)=O UMHUHHJMEXNSIV-CIUDSAMLSA-N 0.000 description 1
- WMLFFCRUSPNENW-ZLUOBGJFSA-N Asp-Ser-Ala Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(O)=O WMLFFCRUSPNENW-ZLUOBGJFSA-N 0.000 description 1
- PLNJUJGNLDSFOP-UWJYBYFXSA-N Asp-Tyr-Ala Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](C)C(O)=O PLNJUJGNLDSFOP-UWJYBYFXSA-N 0.000 description 1
- HTSSXFASOUSJQG-IHPCNDPISA-N Asp-Tyr-Trp Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(O)=O HTSSXFASOUSJQG-IHPCNDPISA-N 0.000 description 1
- GIKOVDMXBAFXDF-NHCYSSNCSA-N Asp-Val-Leu Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O GIKOVDMXBAFXDF-NHCYSSNCSA-N 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- SZQCDCKIGWQAQN-FXQIFTODSA-N Cys-Arg-Ala Chemical compound [H]N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(O)=O SZQCDCKIGWQAQN-FXQIFTODSA-N 0.000 description 1
- GEEXORWTBTUOHC-FXQIFTODSA-N Cys-Arg-Ser Chemical compound C(C[C@@H](C(=O)N[C@@H](CO)C(=O)O)NC(=O)[C@H](CS)N)CN=C(N)N GEEXORWTBTUOHC-FXQIFTODSA-N 0.000 description 1
- BBQIWFFTTQTNOC-AVGNSLFASA-N Cys-Phe-Gln Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)[C@H](CS)N BBQIWFFTTQTNOC-AVGNSLFASA-N 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- WMOMPXKOKASNBK-PEFMBERDSA-N Gln-Asn-Ile Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O WMOMPXKOKASNBK-PEFMBERDSA-N 0.000 description 1
- CRRFJBGUGNNOCS-PEFMBERDSA-N Gln-Asp-Ile Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O CRRFJBGUGNNOCS-PEFMBERDSA-N 0.000 description 1
- NVEASDQHBRZPSU-BQBZGAKWSA-N Gln-Gln-Gly Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(O)=O NVEASDQHBRZPSU-BQBZGAKWSA-N 0.000 description 1
- RBWKVOSARCFSQQ-FXQIFTODSA-N Gln-Gln-Ser Chemical compound NC(=O)CC[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(O)=O RBWKVOSARCFSQQ-FXQIFTODSA-N 0.000 description 1
- ZNZPKVQURDQFFS-FXQIFTODSA-N Gln-Glu-Ser Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(O)=O ZNZPKVQURDQFFS-FXQIFTODSA-N 0.000 description 1
- FGYPOQPQTUNESW-IUCAKERBSA-N Gln-Gly-Leu Chemical compound CC(C)C[C@@H](C(=O)O)NC(=O)CNC(=O)[C@H](CCC(=O)N)N FGYPOQPQTUNESW-IUCAKERBSA-N 0.000 description 1
- XSBGUANSZDGULP-IUCAKERBSA-N Gln-Gly-Lys Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CCCCN)C(O)=O XSBGUANSZDGULP-IUCAKERBSA-N 0.000 description 1
- ITZWDGBYBPUZRG-KBIXCLLPSA-N Gln-Ile-Ser Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(O)=O ITZWDGBYBPUZRG-KBIXCLLPSA-N 0.000 description 1
- VZRAXPGTUNDIDK-GUBZILKMSA-N Gln-Leu-Asn Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)O)NC(=O)[C@H](CCC(=O)N)N VZRAXPGTUNDIDK-GUBZILKMSA-N 0.000 description 1
- FTTHLXOMDMLKKW-FHWLQOOXSA-N Gln-Phe-Phe Chemical compound C([C@H](NC(=O)[C@H](CCC(N)=O)N)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 FTTHLXOMDMLKKW-FHWLQOOXSA-N 0.000 description 1
- OZEQPCDLCDRCGY-SOUVJXGZSA-N Gln-Phe-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CCC(=O)N)N)C(=O)O OZEQPCDLCDRCGY-SOUVJXGZSA-N 0.000 description 1
- LKDIBBOKUAASNP-FXQIFTODSA-N Glu-Ala-Glu Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(O)=O LKDIBBOKUAASNP-FXQIFTODSA-N 0.000 description 1
- IESFZVCAVACGPH-PEFMBERDSA-N Glu-Asp-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](N)CCC(O)=O IESFZVCAVACGPH-PEFMBERDSA-N 0.000 description 1
- JVZLZVJTIXVIHK-SXNHZJKMSA-N Glu-Trp-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](CC1=CNC2=CC=CC=C21)NC(=O)[C@H](CCC(=O)O)N JVZLZVJTIXVIHK-SXNHZJKMSA-N 0.000 description 1
- CGWHAXBNGYQBBK-JBACZVJFSA-N Glu-Trp-Tyr Chemical compound C([C@H](NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CCC(O)=O)N)C(O)=O)C1=CC=C(O)C=C1 CGWHAXBNGYQBBK-JBACZVJFSA-N 0.000 description 1
- OCDLPQDYTJPWNG-YUMQZZPRSA-N Gly-Asn-Lys Chemical compound C(CCN)C[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)N)NC(=O)CN OCDLPQDYTJPWNG-YUMQZZPRSA-N 0.000 description 1
- LURCIJSJAKFCRO-QWRGUYRKSA-N Gly-Asn-Tyr Chemical compound [H]NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O LURCIJSJAKFCRO-QWRGUYRKSA-N 0.000 description 1
- BYYNJRSNDARRBX-YFKPBYRVSA-N Gly-Gln-Gly Chemical compound NCC(=O)N[C@@H](CCC(N)=O)C(=O)NCC(O)=O BYYNJRSNDARRBX-YFKPBYRVSA-N 0.000 description 1
- BPQYBFAXRGMGGY-LAEOZQHASA-N Gly-Gln-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)N)NC(=O)CN BPQYBFAXRGMGGY-LAEOZQHASA-N 0.000 description 1
- VBOBNHSVQKKTOT-YUMQZZPRSA-N Gly-Lys-Ala Chemical compound [H]NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(O)=O VBOBNHSVQKKTOT-YUMQZZPRSA-N 0.000 description 1
- JJGBXTYGTKWGAT-YUMQZZPRSA-N Gly-Pro-Glu Chemical compound NCC(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(O)=O JJGBXTYGTKWGAT-YUMQZZPRSA-N 0.000 description 1
- NSVOVKWEKGEOQB-LURJTMIESA-N Gly-Pro-Gly Chemical compound NCC(=O)N1CCC[C@H]1C(=O)NCC(O)=O NSVOVKWEKGEOQB-LURJTMIESA-N 0.000 description 1
- JNGHLWWFPGIJER-STQMWFEESA-N Gly-Pro-Tyr Chemical compound NCC(=O)N1CCC[C@H]1C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 JNGHLWWFPGIJER-STQMWFEESA-N 0.000 description 1
- SOEGEPHNZOISMT-BYPYZUCNSA-N Gly-Ser-Gly Chemical compound NCC(=O)N[C@@H](CO)C(=O)NCC(O)=O SOEGEPHNZOISMT-BYPYZUCNSA-N 0.000 description 1
- DBUNZBWUWCIELX-JHEQGTHGSA-N Gly-Thr-Glu Chemical compound [H]NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(O)=O)C(O)=O DBUNZBWUWCIELX-JHEQGTHGSA-N 0.000 description 1
- CUVBTVWFVIIDOC-YEPSODPASA-N Gly-Thr-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)CN CUVBTVWFVIIDOC-YEPSODPASA-N 0.000 description 1
- DNAZKGFYFRGZIH-QWRGUYRKSA-N Gly-Tyr-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)CN)CC1=CC=C(O)C=C1 DNAZKGFYFRGZIH-QWRGUYRKSA-N 0.000 description 1
- GBYYQVBXFVDJPJ-WLTAIBSBSA-N Gly-Tyr-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CC1=CC=C(C=C1)O)NC(=O)CN)O GBYYQVBXFVDJPJ-WLTAIBSBSA-N 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- AVQNTYBAFBKMDL-WDSOQIARSA-N His-Pro-Trp Chemical compound N[C@@H](Cc1cnc[nH]1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(O)=O AVQNTYBAFBKMDL-WDSOQIARSA-N 0.000 description 1
- ZHHLTWUOWXHVQJ-YUMQZZPRSA-N His-Ser-Gly Chemical compound C1=C(NC=N1)C[C@@H](C(=O)N[C@@H](CO)C(=O)NCC(=O)O)N ZHHLTWUOWXHVQJ-YUMQZZPRSA-N 0.000 description 1
- QYZYJFXHXYUZMZ-UGYAYLCHSA-N Ile-Asn-Asn Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CC(=O)N)C(=O)O)N QYZYJFXHXYUZMZ-UGYAYLCHSA-N 0.000 description 1
- WCNWGAUZWWSYDG-SVSWQMSJSA-N Ile-Thr-Ser Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)O)N WCNWGAUZWWSYDG-SVSWQMSJSA-N 0.000 description 1
- NUEHSWNAFIEBCQ-NAKRPEOUSA-N Ile-Val-Cys Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CS)C(=O)O)N NUEHSWNAFIEBCQ-NAKRPEOUSA-N 0.000 description 1
- 108010065920 Insulin Lispro Proteins 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 241000581650 Ivesia Species 0.000 description 1
- PMGDADKJMCOXHX-UHFFFAOYSA-N L-Arginyl-L-glutamin-acetat Natural products NC(=N)NCCCC(N)C(=O)NC(CCC(N)=O)C(O)=O PMGDADKJMCOXHX-UHFFFAOYSA-N 0.000 description 1
- TYYLDKGBCJGJGW-UHFFFAOYSA-N L-tryptophan-L-tyrosine Natural products C=1NC2=CC=CC=C2C=1CC(N)C(=O)NC(C(O)=O)CC1=CC=C(O)C=C1 TYYLDKGBCJGJGW-UHFFFAOYSA-N 0.000 description 1
- USTCFDAQCLDPBD-XIRDDKMYSA-N Leu-Asn-Trp Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)O)N USTCFDAQCLDPBD-XIRDDKMYSA-N 0.000 description 1
- KAFOIVJDVSZUMD-UHFFFAOYSA-N Leu-Gln-Gln Natural products CC(C)CC(N)C(=O)NC(CCC(N)=O)C(=O)NC(CCC(N)=O)C(O)=O KAFOIVJDVSZUMD-UHFFFAOYSA-N 0.000 description 1
- FQZPTCNSNPWHLJ-AVGNSLFASA-N Leu-Gln-Lys Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(O)=O FQZPTCNSNPWHLJ-AVGNSLFASA-N 0.000 description 1
- HPBCTWSUJOGJSH-MNXVOIDGSA-N Leu-Glu-Ile Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O HPBCTWSUJOGJSH-MNXVOIDGSA-N 0.000 description 1
- FEHQLKKBVJHSEC-SZMVWBNQSA-N Leu-Glu-Trp Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](N)CC(C)C)C(O)=O)=CNC2=C1 FEHQLKKBVJHSEC-SZMVWBNQSA-N 0.000 description 1
- NRFGTHFONZYFNY-MGHWNKPDSA-N Leu-Ile-Tyr Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 NRFGTHFONZYFNY-MGHWNKPDSA-N 0.000 description 1
- XOWMDXHFSBCAKQ-SRVKXCTJSA-N Leu-Ser-Leu Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CC(C)C XOWMDXHFSBCAKQ-SRVKXCTJSA-N 0.000 description 1
- AIRZWUMAHCDDHR-KKUMJFAQSA-N Lys-Leu-Leu Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O AIRZWUMAHCDDHR-KKUMJFAQSA-N 0.000 description 1
- WGILOYIKJVQUPT-DCAQKATOSA-N Lys-Pro-Asp Chemical compound [H]N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(O)=O)C(O)=O WGILOYIKJVQUPT-DCAQKATOSA-N 0.000 description 1
- PDIDTSZKKFEDMB-UWVGGRQHSA-N Lys-Pro-Gly Chemical compound [H]N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)NCC(O)=O PDIDTSZKKFEDMB-UWVGGRQHSA-N 0.000 description 1
- DLCAXBGXGOVUCD-PPCPHDFISA-N Lys-Thr-Ile Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O DLCAXBGXGOVUCD-PPCPHDFISA-N 0.000 description 1
- ABHVWYPPHDYFNY-WDSOQIARSA-N Met-His-Trp Chemical compound C([C@H](NC(=O)[C@@H](N)CCSC)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)C1=CN=CN1 ABHVWYPPHDYFNY-WDSOQIARSA-N 0.000 description 1
- WUGMRIBZSVSJNP-UHFFFAOYSA-N N-L-alanyl-L-tryptophan Natural products C1=CC=C2C(CC(NC(=O)C(N)C)C(O)=O)=CNC2=C1 WUGMRIBZSVSJNP-UHFFFAOYSA-N 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 108010002747 Pfu DNA polymerase Proteins 0.000 description 1
- CUMXHKAOHNWRFQ-BZSNNMDCSA-N Phe-Asp-Tyr Chemical compound C([C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)C1=CC=CC=C1 CUMXHKAOHNWRFQ-BZSNNMDCSA-N 0.000 description 1
- FSPGBMWPNMRWDB-AVGNSLFASA-N Phe-Cys-Gln Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(=O)N)C(=O)O)N FSPGBMWPNMRWDB-AVGNSLFASA-N 0.000 description 1
- OPEVYHFJXLCCRT-AVGNSLFASA-N Phe-Gln-Ser Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(O)=O OPEVYHFJXLCCRT-AVGNSLFASA-N 0.000 description 1
- NAXPHWZXEXNDIW-JTQLQIEISA-N Phe-Gly-Gly Chemical compound OC(=O)CNC(=O)CNC(=O)[C@@H](N)CC1=CC=CC=C1 NAXPHWZXEXNDIW-JTQLQIEISA-N 0.000 description 1
- GNRMAQSIROFNMI-IXOXFDKPSA-N Phe-Thr-Ser Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(O)=O GNRMAQSIROFNMI-IXOXFDKPSA-N 0.000 description 1
- GCFNFKNPCMBHNT-IRXDYDNUSA-N Phe-Tyr-Gly Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CC2=CC=C(C=C2)O)C(=O)NCC(=O)O)N GCFNFKNPCMBHNT-IRXDYDNUSA-N 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 229920002538 Polyethylene Glycol 20000 Polymers 0.000 description 1
- MGDFPGCFVJFITQ-CIUDSAMLSA-N Pro-Glu-Asp Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O MGDFPGCFVJFITQ-CIUDSAMLSA-N 0.000 description 1
- CLNJSLSHKJECME-BQBZGAKWSA-N Pro-Gly-Ala Chemical compound OC(=O)[C@H](C)NC(=O)CNC(=O)[C@@H]1CCCN1 CLNJSLSHKJECME-BQBZGAKWSA-N 0.000 description 1
- JMVQDLDPDBXAAX-YUMQZZPRSA-N Pro-Gly-Gln Chemical compound NC(=O)CC[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H]1CCCN1 JMVQDLDPDBXAAX-YUMQZZPRSA-N 0.000 description 1
- RMODQFBNDDENCP-IHRRRGAJSA-N Pro-Lys-Leu Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(O)=O RMODQFBNDDENCP-IHRRRGAJSA-N 0.000 description 1
- SEZGGSHLMROBFX-CIUDSAMLSA-N Pro-Ser-Gln Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(O)=O SEZGGSHLMROBFX-CIUDSAMLSA-N 0.000 description 1
- LNICFEXCAHIJOR-DCAQKATOSA-N Pro-Ser-Leu Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(O)=O LNICFEXCAHIJOR-DCAQKATOSA-N 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- WTUJZHKANPDPIN-CIUDSAMLSA-N Ser-Ala-Lys Chemical compound C[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CO)N WTUJZHKANPDPIN-CIUDSAMLSA-N 0.000 description 1
- HBZBPFLJNDXRAY-FXQIFTODSA-N Ser-Ala-Val Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(O)=O HBZBPFLJNDXRAY-FXQIFTODSA-N 0.000 description 1
- KYKKKSWGEPFUMR-NAKRPEOUSA-N Ser-Arg-Ile Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O KYKKKSWGEPFUMR-NAKRPEOUSA-N 0.000 description 1
- WDXYVIIVDIDOSX-DCAQKATOSA-N Ser-Arg-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CO)CCCN=C(N)N WDXYVIIVDIDOSX-DCAQKATOSA-N 0.000 description 1
- HBOABDXGTMMDSE-GUBZILKMSA-N Ser-Arg-Val Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(O)=O HBOABDXGTMMDSE-GUBZILKMSA-N 0.000 description 1
- BYIROAKULFFTEK-CIUDSAMLSA-N Ser-Asp-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](N)CO BYIROAKULFFTEK-CIUDSAMLSA-N 0.000 description 1
- MMAPOBOTRUVNKJ-ZLUOBGJFSA-N Ser-Asp-Ser Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)O)NC(=O)[C@H](CO)N)C(=O)O MMAPOBOTRUVNKJ-ZLUOBGJFSA-N 0.000 description 1
- BLPYXIXXCFVIIF-FXQIFTODSA-N Ser-Cys-Arg Chemical compound C(C[C@@H](C(=O)O)NC(=O)[C@H](CS)NC(=O)[C@H](CO)N)CN=C(N)N BLPYXIXXCFVIIF-FXQIFTODSA-N 0.000 description 1
- CDVFZMOFNJPUDD-ACZMJKKPSA-N Ser-Gln-Asn Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O CDVFZMOFNJPUDD-ACZMJKKPSA-N 0.000 description 1
- ULVMNZOKDBHKKI-ACZMJKKPSA-N Ser-Gln-Asp Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O ULVMNZOKDBHKKI-ACZMJKKPSA-N 0.000 description 1
- HJEBZBMOTCQYDN-ACZMJKKPSA-N Ser-Glu-Asp Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O HJEBZBMOTCQYDN-ACZMJKKPSA-N 0.000 description 1
- XXXAXOWMBOKTRN-XPUUQOCRSA-N Ser-Gly-Val Chemical compound [H]N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C(C)C)C(O)=O XXXAXOWMBOKTRN-XPUUQOCRSA-N 0.000 description 1
- LQESNKGTTNHZPZ-GHCJXIJMSA-N Ser-Ile-Asn Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(O)=O LQESNKGTTNHZPZ-GHCJXIJMSA-N 0.000 description 1
- UIPXCLNLUUAMJU-JBDRJPRFSA-N Ser-Ile-Ser Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(O)=O UIPXCLNLUUAMJU-JBDRJPRFSA-N 0.000 description 1
- UBRMZSHOOIVJPW-SRVKXCTJSA-N Ser-Leu-Lys Chemical compound OC[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(O)=O UBRMZSHOOIVJPW-SRVKXCTJSA-N 0.000 description 1
- KCGIREHVWRXNDH-GARJFASQSA-N Ser-Leu-Pro Chemical compound CC(C)C[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CO)N KCGIREHVWRXNDH-GARJFASQSA-N 0.000 description 1
- YUJLIIRMIAGMCQ-CIUDSAMLSA-N Ser-Leu-Ser Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(O)=O YUJLIIRMIAGMCQ-CIUDSAMLSA-N 0.000 description 1
- MUJQWSAWLLRJCE-KATARQTJSA-N Ser-Leu-Thr Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O MUJQWSAWLLRJCE-KATARQTJSA-N 0.000 description 1
- HDBOEVPDIDDEPC-CIUDSAMLSA-N Ser-Lys-Asn Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(O)=O HDBOEVPDIDDEPC-CIUDSAMLSA-N 0.000 description 1
- SRSPTFBENMJHMR-WHFBIAKZSA-N Ser-Ser-Gly Chemical compound OC[C@H](N)C(=O)N[C@@H](CO)C(=O)NCC(O)=O SRSPTFBENMJHMR-WHFBIAKZSA-N 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 108010006785 Taq Polymerase Proteins 0.000 description 1
- 241001052560 Thallis Species 0.000 description 1
- CAJFZCICSVBOJK-SHGPDSBTSA-N Thr-Ala-Thr Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O CAJFZCICSVBOJK-SHGPDSBTSA-N 0.000 description 1
- DGDCHPCRMWEOJR-FQPOAREZSA-N Thr-Ala-Tyr Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 DGDCHPCRMWEOJR-FQPOAREZSA-N 0.000 description 1
- KRPKYGOFYUNIGM-XVSYOHENSA-N Thr-Asp-Phe Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)O)N)O KRPKYGOFYUNIGM-XVSYOHENSA-N 0.000 description 1
- UZJDBCHMIQXLOQ-HEIBUPTGSA-N Thr-Cys-Thr Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CS)C(=O)N[C@@H]([C@@H](C)O)C(=O)O)N)O UZJDBCHMIQXLOQ-HEIBUPTGSA-N 0.000 description 1
- PAXANSWUSVPFNK-IUKAMOBKSA-N Thr-Ile-Asn Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)O)NC(=O)[C@H]([C@@H](C)O)N PAXANSWUSVPFNK-IUKAMOBKSA-N 0.000 description 1
- JRAUIKJSEAKTGD-TUBUOCAGSA-N Thr-Ile-His Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)NC(=O)[C@H]([C@@H](C)O)N JRAUIKJSEAKTGD-TUBUOCAGSA-N 0.000 description 1
- FQPDRTDDEZXCEC-SVSWQMSJSA-N Thr-Ile-Ser Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(O)=O FQPDRTDDEZXCEC-SVSWQMSJSA-N 0.000 description 1
- MECLEFZMPPOEAC-VOAKCMCISA-N Thr-Leu-Lys Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)O)N)O MECLEFZMPPOEAC-VOAKCMCISA-N 0.000 description 1
- YOOAQCZYZHGUAZ-KATARQTJSA-N Thr-Leu-Ser Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(O)=O YOOAQCZYZHGUAZ-KATARQTJSA-N 0.000 description 1
- SPVHQURZJCUDQC-VOAKCMCISA-N Thr-Lys-Leu Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(O)=O SPVHQURZJCUDQC-VOAKCMCISA-N 0.000 description 1
- DEGCBBCMYWNJNA-RHYQMDGZSA-N Thr-Pro-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)[C@@H](C)O DEGCBBCMYWNJNA-RHYQMDGZSA-N 0.000 description 1
- IVDFVBVIVLJJHR-LKXGYXEUSA-N Thr-Ser-Asp Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(O)=O IVDFVBVIVLJJHR-LKXGYXEUSA-N 0.000 description 1
- AHERARIZBPOMNU-KATARQTJSA-N Thr-Ser-Leu Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(O)=O AHERARIZBPOMNU-KATARQTJSA-N 0.000 description 1
- HUPLKEHTTQBXSC-YJRXYDGGSA-N Thr-Ser-Tyr Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 HUPLKEHTTQBXSC-YJRXYDGGSA-N 0.000 description 1
- ZMYCLHFLHRVOEA-HEIBUPTGSA-N Thr-Thr-Ser Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(O)=O ZMYCLHFLHRVOEA-HEIBUPTGSA-N 0.000 description 1
- NJGMALCNYAMYCB-JRQIVUDYSA-N Thr-Tyr-Asn Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(N)=O)C(O)=O NJGMALCNYAMYCB-JRQIVUDYSA-N 0.000 description 1
- MNYNCKZAEIAONY-XGEHTFHBSA-N Thr-Val-Ser Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CO)C(O)=O MNYNCKZAEIAONY-XGEHTFHBSA-N 0.000 description 1
- 101710120037 Toxin CcdB Proteins 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- HQJOVVWAPQPYDS-ZFWWWQNUSA-N Trp-Gly-Arg Chemical compound [H]N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(O)=O HQJOVVWAPQPYDS-ZFWWWQNUSA-N 0.000 description 1
- GQHAIUPYZPTADF-FDARSICLSA-N Trp-Ile-Arg Chemical compound C1=CC=C2C(C[C@H](N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O)=CNC2=C1 GQHAIUPYZPTADF-FDARSICLSA-N 0.000 description 1
- YXSSXUIBUJGHJY-SFJXLCSZSA-N Trp-Thr-Phe Chemical compound C([C@H](NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C2=CC=CC=C2NC=1)[C@H](O)C)C(O)=O)C1=CC=CC=C1 YXSSXUIBUJGHJY-SFJXLCSZSA-N 0.000 description 1
- CDRYEAWHKJSGAF-BPNCWPANSA-N Tyr-Ala-Met Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](C)C(=O)N[C@@H](CCSC)C(O)=O CDRYEAWHKJSGAF-BPNCWPANSA-N 0.000 description 1
- XMNDQSYABVWZRK-BZSNNMDCSA-N Tyr-Asn-Phe Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O XMNDQSYABVWZRK-BZSNNMDCSA-N 0.000 description 1
- VTFWAGGJDRSQFG-MELADBBJSA-N Tyr-Asn-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC2=CC=C(C=C2)O)N)C(=O)O VTFWAGGJDRSQFG-MELADBBJSA-N 0.000 description 1
- QUILOGWWLXMSAT-IHRRRGAJSA-N Tyr-Gln-Gln Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(O)=O QUILOGWWLXMSAT-IHRRRGAJSA-N 0.000 description 1
- NMKJPMCEKQHRPD-IRXDYDNUSA-N Tyr-Gly-Tyr Chemical compound C([C@H](N)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)C1=CC=C(O)C=C1 NMKJPMCEKQHRPD-IRXDYDNUSA-N 0.000 description 1
- QPOUERMDWKKZEG-HJPIBITLSA-N Tyr-Ser-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 QPOUERMDWKKZEG-HJPIBITLSA-N 0.000 description 1
- MQGGXGKQSVEQHR-KKUMJFAQSA-N Tyr-Ser-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 MQGGXGKQSVEQHR-KKUMJFAQSA-N 0.000 description 1
- LDKDSFQSEUOCOO-RPTUDFQQSA-N Tyr-Thr-Phe Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O LDKDSFQSEUOCOO-RPTUDFQQSA-N 0.000 description 1
- WQOHKVRQDLNDIL-YJRXYDGGSA-N Tyr-Thr-Ser Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(O)=O WQOHKVRQDLNDIL-YJRXYDGGSA-N 0.000 description 1
- KSGKJSFPWSMJHK-JNPHEJMOSA-N Tyr-Tyr-Thr Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H]([C@@H](C)O)C(O)=O KSGKJSFPWSMJHK-JNPHEJMOSA-N 0.000 description 1
- SMUWZUSWMWVOSL-JYJNAYRXSA-N Tyr-Val-Met Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCSC)C(=O)O)NC(=O)[C@H](CC1=CC=C(C=C1)O)N SMUWZUSWMWVOSL-JYJNAYRXSA-N 0.000 description 1
- HIZMLPKDJAXDRG-FXQIFTODSA-N Val-Cys-Ser Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CO)C(=O)O)N HIZMLPKDJAXDRG-FXQIFTODSA-N 0.000 description 1
- WBAJDGWKRIHOAC-GVXVVHGQSA-N Val-Lys-Gln Chemical compound [H]N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(O)=O WBAJDGWKRIHOAC-GVXVVHGQSA-N 0.000 description 1
- IEBGHUMBJXIXHM-AVGNSLFASA-N Val-Lys-Met Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCSC)C(=O)O)N IEBGHUMBJXIXHM-AVGNSLFASA-N 0.000 description 1
- SSYBNWFXCFNRFN-GUBZILKMSA-N Val-Pro-Ser Chemical compound CC(C)[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(O)=O SSYBNWFXCFNRFN-GUBZILKMSA-N 0.000 description 1
- VHIZXDZMTDVFGX-DCAQKATOSA-N Val-Ser-Leu Chemical compound CC(C)C[C@@H](C(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](C(C)C)N VHIZXDZMTDVFGX-DCAQKATOSA-N 0.000 description 1
- PZTZYZUTCPZWJH-FXQIFTODSA-N Val-Ser-Ser Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)O)N PZTZYZUTCPZWJH-FXQIFTODSA-N 0.000 description 1
- YQYFYUSYEDNLSD-YEPSODPASA-N Val-Thr-Gly Chemical compound CC(C)[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(O)=O YQYFYUSYEDNLSD-YEPSODPASA-N 0.000 description 1
- JAIZPWVHPQRYOU-ZJDVBMNYSA-N Val-Thr-Thr Chemical compound C[C@H]([C@@H](C(=O)N[C@@H]([C@@H](C)O)C(=O)O)NC(=O)[C@H](C(C)C)N)O JAIZPWVHPQRYOU-ZJDVBMNYSA-N 0.000 description 1
- OWFGFHQMSBTKLX-UFYCRDLUSA-N Val-Tyr-Tyr Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](CC2=CC=C(C=C2)O)C(=O)O)N OWFGFHQMSBTKLX-UFYCRDLUSA-N 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 108010081404 acein-2 Proteins 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 108010086434 alanyl-seryl-glycine Proteins 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 238000011091 antibody purification Methods 0.000 description 1
- 108010008355 arginyl-glutamine Proteins 0.000 description 1
- 108010091092 arginyl-glycyl-proline Proteins 0.000 description 1
- 108010047857 aspartylglycine Proteins 0.000 description 1
- 238000010009 beating Methods 0.000 description 1
- 238000010170 biological method Methods 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 229910002091 carbon monoxide Inorganic materials 0.000 description 1
- 238000010370 cell cloning Methods 0.000 description 1
- 230000007910 cell fusion Effects 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- NKLPQNGYXWVELD-UHFFFAOYSA-M coomassie brilliant blue Chemical compound [Na+].C1=CC(OCC)=CC=C1NC1=CC=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C=CC(=CC=2)N(CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=C1 NKLPQNGYXWVELD-UHFFFAOYSA-M 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 230000000249 desinfective effect Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- FSXRLASFHBWESK-UHFFFAOYSA-N dipeptide phenylalanyl-tyrosine Natural products C=1C=C(O)C=CC=1CC(C(O)=O)NC(=O)C(N)CC1=CC=CC=C1 FSXRLASFHBWESK-UHFFFAOYSA-N 0.000 description 1
- 239000012154 double-distilled water Substances 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 239000012149 elution buffer Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012595 freezing medium Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 108010057083 glutamyl-aspartyl-leucine Proteins 0.000 description 1
- 108010079413 glycyl-prolyl-glutamic acid Proteins 0.000 description 1
- 108010010147 glycylglutamine Proteins 0.000 description 1
- 108010087823 glycyltyrosine Proteins 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 208000027096 gram-negative bacterial infections Diseases 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 238000000703 high-speed centrifugation Methods 0.000 description 1
- 108010085325 histidylproline Proteins 0.000 description 1
- 108010018006 histidylserine Proteins 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000010030 laminating Methods 0.000 description 1
- 108010034529 leucyl-lysine Proteins 0.000 description 1
- GZQKNULLWNGMCW-PWQABINMSA-N lipid A (E. coli) Chemical compound O1[C@H](CO)[C@@H](OP(O)(O)=O)[C@H](OC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC)[C@@H](NC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCC)[C@@H]1OC[C@@H]1[C@@H](O)[C@H](OC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](NC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](OP(O)(O)=O)O1 GZQKNULLWNGMCW-PWQABINMSA-N 0.000 description 1
- 239000004973 liquid crystal related substance Substances 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 108010073025 phenylalanylphenylalanine Proteins 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 238000012257 pre-denaturation Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 108010029020 prolylglycine Proteins 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 230000008261 resistance mechanism Effects 0.000 description 1
- 238000006748 scratching Methods 0.000 description 1
- 230000002393 scratching effect Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 238000009210 therapy by ultrasound Methods 0.000 description 1
- 108010033670 threonyl-aspartyl-tyrosine Proteins 0.000 description 1
- 108010072986 threonyl-seryl-lysine Proteins 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 108010038745 tryptophylglycine Proteins 0.000 description 1
- 108010044292 tryptophyltyrosine Proteins 0.000 description 1
- 108010073969 valyllysine Proteins 0.000 description 1
- 108010009962 valyltyrosine Proteins 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 108010027345 wheylin-1 peptide Proteins 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2869—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56911—Bacteria
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
- G01N33/743—Steroid hormones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
- G01N2333/723—Steroid/thyroid hormone superfamily, e.g. GR, EcR, androgen receptor, oestrogen receptor
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/91—Transferases (2.)
- G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- G01N2333/91205—Phosphotransferases in general
- G01N2333/9129—Transferases for other substituted phosphate groups (2.7.8)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/44—Multiple drug resistance
Abstract
本发明提供鼠抗MCR‑1/MCR‑2蛋白杂交瘤细胞株,单克隆抗体及应用,通过小鼠杂交瘤单克隆抗体筛选及RT‑PCR法克隆Ig可变区基因,获得稳定分泌鼠抗MCR‑1/MCR‑2蛋白抗体的杂交瘤细胞株及其可变区序列;通过系统性评价,鼠抗MCR‑1/MCR‑2蛋白抗体在各方面均有较佳表现,效价达到了1:1280000以上,适合作为免疫诊断试剂用于制备多粘菌素耐药菌株体外诊断试剂盒。
Description
技术领域
本发明属于抗体制备技术领域,尤其是涉及一种鼠抗MCR-1、MCR-2蛋白杂交瘤细胞株,单克隆抗体及应用。
背景技术
多黏菌素(polymyxin)是目前用于多重耐药和泛耐药革兰氏阴性细菌感染临床治疗的最后选择,近年来由于多粘菌素的临床使用增加,耐药菌株数量也逐年增加,虽然目前细菌的对多粘菌素耐药性并不强,却可能导致无药可医的地步,如何有效遏制耐药性的蔓延成为一个全球公关卫生问题。在多种药机制中,介导脂质A磷酸乙醇胺(PEtn)添加相关MCR基因被发现在多种质粒中,并可通过质粒在不同细菌中水平传播,甚至可以与其他耐药基因共同存在于同一质粒,表达后产生多种耐药机制。加之抗生素的不合理应用使得细菌耐药能力不断增强,给临床医师选用抗生素造成了极大的困扰。
实验室检测MCR介导的多黏菌素耐药主要是通过分子生物学法。研发具有自主知识产权的MCR蛋白快速诊断产品对于快速鉴定多黏菌素耐药菌株及其耐药机制,优化多黏菌素治疗方案,延长多黏菌素作为最后一线治疗药物的使用寿命具有重要意义。
发明内容
为解决上述技术问题,本发明提供一种鼠抗MCR-1、MCR-2蛋白杂交瘤细胞株,单克隆抗体及应用。
本发明采用的技术方案是:鼠抗MCR-1/MCR-2蛋白杂交瘤细胞株,命名为2DG5,保藏编号为CGMCC No.23034;或者命名为1IB10,保藏编号为CGMCC No.23032。
鼠抗MCR-1/MCR-2蛋白抗体,抗体2DG5,包括轻链可变区和重链可变区,轻链可变区包括如SEQ ID NO:1所示的CDRL1、SEQ ID NO:2所示的CDRL2和SEQ ID NO:3所示的CDRL3,重链可变区包括如SEQ ID NO:4所示的CDRH1、SEQ ID NO:5所示的CDRH2和SEQ IDNO:6所示的CDRH3;
SEQ ID NO:1 RASQDINNYLN(CDRL1)
SEQ ID NO:2 YTSRLHS(CDRL2)
SEQ ID NO:3 QQGKTIHPWT(CDRL3)
SEQ ID NO:4 GYSITSDYAWN(CDRH1)
SEQ ID NO:5 QISDSAVTTYNPSLKS(CDRH2)
SEQ ID NO:6 RNFYGYNFFDY(CDRH3)
或者,
抗体1IB10,轻链可变区包括如SEQ ID NO:11所示的CDRL1、SEQ ID NO:12所示的CDRL2和SEQ ID NO:13所示的CDRL3,重链可变区包括如SEQ ID NO:14所示的CDRH1、SEQ IDNO:15所示的CDRH2和SEQ ID NO:16所示的CDRH3;
SEQ ID NO:11 RSSQNIVCSYGNPCLE(CDRL1)
SEQ ID NO:12 KVSNRFS(CDRL2)
SEQ ID NO:13 FQSSHVPWT(CDRL3)
SEQ ID NO:14 GYTFTSYVMH(CDRH1)
SEQ ID NO:15 YFNPYNDGANYNEKFKG(CDRH2)
SEQ ID NO:16 GPYGNYAMDY(CDRH3)
优选地,抗体2DG5轻链可变区氨基酸序列为SEQ ID NO:7所示,重链可变区氨基酸序列为SEQ ID NO:9所示;
SEQ ID NO:7
DIQMTQTTSSLSASLGDRVTINCRASQDINNYLNWYQQKPDGTVKLLIYYTSRLHSGVPSRFSGSGSRTDYSLTISNLEREDIATYFCQQGKTIHPWTFGGGTKLDIKRA
SEQ ID NO:9
VKLQESGPGLVKPSQSLSLTCTVTGYSITSDYAWNWIRQFPGNKLEWMGQISDSAVTTYNPSLKSRISINRDTSKNQFFLQLNSVTPEDTATYYCARRNFYGYNFFDYWGRGTSLTVSSAK
或者,
抗体1IB10轻链可变区氨基酸序列为SEQ ID NO:17所示,重链可变区氨基酸序列为SEQ ID NO:19所示;
SEQ ID NO:17
DVLMTQTPLSLPVSLGDQASISCRSSQNIVCSYGNPCLEWYLQKPGQSPKLLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDLGVYYCFQSSHVPWTFGGGTELEIKR
SEQ ID NO:19
VKLQQSGPELVKPGASVKMSCRASGYTFTSYVMHWVKQKPGQGLEWIGYFNPYNDGANYNEKFKGKATLSSDKSSGTAYMDLSSLTSEDSAVYYCARGPYGNYAMDYWGQGTSVTVSSA
优选地,抗体2DG5由保藏编号为CGMCC No.23034的鼠抗MCR-1/MCR-2蛋白杂交瘤细胞株产生;
或者,
抗体1IB10由保藏编号为CGMCC No.23032的鼠抗MCR-1/MCR-2蛋白杂交瘤细胞株产生。
一种核酸分子,包含编码鼠抗MCR-1/MCR-2蛋白抗体的核苷酸。
优选地,所述核酸分子编码抗体2DG5的轻链可变区的核苷酸序列如SEQ ID NO:8所示,所述核酸分子编码抗体2DG5的重链可变区的核苷酸序列如SEQ ID NO:10所示;
SEQ ID NO:8
GATATCCAGATGACACAGACTACATCCTCCCTGTCTGCCTCTCTGGGAGACAGAGTCACCATCAATTGCAGGGCAAGTCAGGACATTAACAATTATTTAAACTGGTATCAGCAGAAACCAGATGGAACTGTTAAACTCCTGATCTACTACACTTCAAGATTACATTCAGGAGTCCCATCAAGGTTCAGCGGCAGTGGGTCTAGAACAGATTATTCTCTCACCATTAGCAACCTGGAACGAGAAGATATTGCCACTTACTTTTGCCAACAGGGTAAAACGATTCATCCGTGGACGTTCGGTGGAGGCACCAAGCTGGACATCAAACGGGCT
SEQ ID NO:10
GTGAAGCTGCAGGAGTCAGGACCTGGCCTGGTGAAACCTTCTCAGTCTCTGTCCCTCACCTGCACTGTCACTGGCTACTCAATCACCAGTGATTATGCCTGGAACTGGATCCGGCAGTTTCCAGGAAACAAACTGGAGTGGATGGGCCAGATAAGCGACAGTGCTGTCACTACCTACAACCCATCTCTCAAAAGTCGAATCTCTATCAATCGAGACACATCCAAGAACCAGTTCTTCCTGCAGTTGAATTCTGTGACTCCTGAGGACACAGCCACATATTACTGTGCAAGAAGGAACTTCTACGGGTACAATTTTTTTGACTACTGGGGCCGAGGCACCTCTCTCACTGTCTCTTCAGCCAAA
或者,
所述核酸分子编码抗体1IB10的轻链可变区的核苷酸序列如SEQ ID NO:18所示,所述核酸分子编码抗体1IB10的重链可变区的核苷酸序列如SEQ ID NO:20所示;
SEQ ID NO:18
GATGTTTTGATGACCCAGACGCCACTCTCCCTGCCTGTCAGTCTTGGAGATCAAGCCTCCATCTCTTGCAGATCTAGTCAGAACATTGTATGTAGTTATGGAAACCCCTGTTTAGAATGGTACCTGCAGAAACCAGGCCAGTCTCCAAAGCTCCTGATCTACAAAGTTTCCAACCGATTTTCTGGGGTCCCAGACAGGTTCAGTGGCAGTGGATCAGGGACAGATTTCACACTCAAGATCAGCAGAGTGGAGGCTGAGGATCTGGGAGTTTATTACTGCTTTCAAAGTTCACATGTTCCGTGGACGTTCGGTGGAGGCACCGAGCTGGAAATCAAACGG
SEQ ID NO:20
GTGAAGCTGCAGCAGTCTGGACCTGAGCTGGTAAAGCCTGGGGCTTCAGTGAAGATGTCCTGCAGGGCTTCTGGATACACATTCACTAGCTATGTTATGCACTGGGTGAAGCAGAAGCCTGGGCAGGGCCTTGAGTGGATTGGATATTTTAATCCTTACAATGACGGTGCTAACTACAATGAGAAGTTCAAAGGCAAGGCCACACTGTCTTCAGACAAATCCTCCGGCACAGCCTATATGGACCTCAGCAGCCTGACCTCTGAGGACTCTGCGGTCTATTATTGTGCGAGAGGCCCCTATGGTAACTATGCTATGGACTACTGGGGTCAAGGAACCTCAGTCACCGTCTCCTCAGCC
鼠抗MCR-1/MCR-2蛋白抗体在制备检测MCR-1或MCR-2蛋白试剂中的应用。
优选地,将鼠抗MCR-1/MCR-2蛋白抗体用于制备体外诊断试剂盒或微流体芯片,所述体外诊断试剂盒为胶体金免疫试剂盒、化学发光试剂盒、放射免疫试剂盒、酶联免疫试剂盒或荧光免疫试剂盒。
优选地,制备双抗体夹心法免疫胶体金试纸条,抗体2DG5为包被抗体,抗体1IB10为金标抗体;
或者,抗体1IB10为包被抗体,抗体2DG5为金标抗体。
本发明具有的优点和积极效果是:本发明提供两种鼠抗MCR-1/MCR-2蛋白杂交瘤细胞株,分别能够产生两种鼠抗MCR-1/MCR-2蛋白抗体,这两种抗体均能与MCR-1蛋白或MCR-2蛋白发生特异性反应;通过系统性评价,包括对抗体亚型及效价、试剂盒灵敏度、特异性和稳定性的评价,鼠抗MCR-1/MCR-2蛋白单克隆抗体在各方面均有较佳表现,效价达到了1:1280000以上,从而适合作为免疫诊断试剂用于制备检测多黏菌素耐药菌株体外诊断试剂盒。
附图说明
图1是鼠抗MCR-1/MCR-2蛋白蛋白电泳图;
图2是鼠抗MCR-1/MCR-2蛋白抗体蛋白电泳图;
图3胶体金法鼠抗MCR-1/MCR-2蛋白检测卡检测结果。
生物材料:2DG5,保藏日期为2021年9月24日,保藏单位为中国微生物菌种保藏管理委员会普通微生物中心(CGMCC),保藏编号是CGMCC No.23034;
生物材料:1IB10,保藏日期为2021年9月24日,保藏单位为中国微生物菌种保藏管理委员会普通微生物中心(CGMCC),保藏编号是CGMCC No.23032。
具体实施方式
下面对本发明的实施例做出说明。
本发明涉及鼠抗MCR-1/MCR-2蛋白杂交瘤细胞株,生物材料命名为2DG5,属杂交瘤细胞,其保藏编号是CGMCC No. 23034;保藏地为中国微生物菌种保藏管理委员会普通微生物中心,其保藏日期为2021年9月24日,检测为存活。另有一株鼠抗MCR-1/MCR-2蛋白杂交瘤细胞株,生物材料命名为1IB10,属杂交瘤细胞,其保藏编号是CGMCC No.23032;保藏地为中国微生物菌种保藏管理委员会普通微生物中心,其保藏日期为2021年9月24日,检测为存活。
鼠抗MCR-1/MCR-2蛋白杂交瘤细胞株生产得到的抗体2DG5,包括轻链可变区和重链可变区,轻链可变区包括如SEQ ID NO:1所示的CDRL1、SEQ ID NO:2所示的CDRL2和SEQID NO:3所示的CDRL3,重链可变区包括如SEQ ID NO:4所示的CDRH1、SEQ ID NO:5所示的CDRH2和SEQ ID NO:6所示的CDRH3;
SEQ ID NO:1 RASQDINNYLN(CDRL1)
SEQ ID NO:2 YTSRLHS(CDRL2)
SEQ ID NO:3 QQGKTIHPWT(CDRL3)
SEQ ID NO:4 GYSITSDYAWN(CDRH1)
SEQ ID NO:5 QISDSAVTTYNPSLKS(CDRH2)
SEQ ID NO:6 RNFYGYNFFDY(CDRH3)
抗体2DG5轻链可变区氨基酸序列为SEQ ID NO:7所示,重链可变区氨基酸序列为SEQ ID NO:9所示;
SEQ ID NO:7
DIQMTQTTSSLSASLGDRVTINCRASQDINNYLNWYQQKPDGTVKLLIYYTSRLHSGVPSRFSGSGSRTDYSLTISNLEREDIATYFCQQGKTIHPWTFGGGTKLDIKRA
SEQ ID NO:9
VKLQESGPGLVKPSQSLSLTCTVTGYSITSDYAWNWIRQFPGNKLEWMGQISDSAVTTYNPSLKSRISINRDTSKNQFFLQLNSVTPEDTATYYCARRNFYGYNFFDYWGRGTSLTVSSAK
编码抗体2DG5的轻链可变区的核苷酸序列如SEQ ID NO:8所示,编码抗体2DG5的重链可变区的核苷酸序列如SEQ ID NO:10所示;
SEQ ID NO:8
GATATCCAGATGACACAGACTACATCCTCCCTGTCTGCCTCTCTGGGAGACAGAGTCACCATCAATTGCAGGGCAAGTCAGGACATTAACAATTATTTAAACTGGTATCAGCAGAAACCAGATGGAACTGTTAAACTCCTGATCTACTACACTTCAAGATTACATTCAGGAGTCCCATCAAGGTTCAGCGGCAGTGGGTCTAGAACAGATTATTCTCTCACCATTAGCAACCTGGAACGAGAAGATATTGCCACTTACTTTTGCCAACAGGGTAAAACGATTCATCCGTGGACGTTCGGTGGAGGCACCAAGCTGGACATCAAACGGGCT
SEQ ID NO:10
GTGAAGCTGCAGGAGTCAGGACCTGGCCTGGTGAAACCTTCTCAGTCTCTGTCCCTCACCTGCACTGTCACTGGCTACTCAATCACCAGTGATTATGCCTGGAACTGGATCCGGCAGTTTCCAGGAAACAAACTGGAGTGGATGGGCCAGATAAGCGACAGTGCTGTCACTACCTACAACCCATCTCTCAAAAGTCGAATCTCTATCAATCGAGACACATCCAAGAACCAGTTCTTCCTGCAGTTGAATTCTGTGACTCCTGAGGACACAGCCACATATTACTGTGCAAGAAGGAACTTCTACGGGTACAATTTTTTTGACTACTGGGGCCGAGGCACCTCTCTCACTGTCTCTTCAGCCAAA
鼠抗MCR-1/MCR-2蛋白杂交瘤细胞株生产得到的抗体1IB10,轻链可变区包括如SEQ ID NO:11所示的CDRL1、SEQ ID NO:12所示的CDRL2和SEQ ID NO:13所示的CDRL3,重链可变区包括如SEQ ID NO:14所示的CDRH1、SEQ ID NO:15所示的CDRH2和SEQ ID NO:16所示的CDRH3;
SEQ ID NO:11 RSSQNIVCSYGNPCLE(CDRL1)
SEQ ID NO:12 KVSNRFS(CDRL2)
SEQ ID NO:13 FQSSHVPWT(CDRL3)
SEQ ID NO:14 GYTFTSYVMH(CDRH1)
SEQ ID NO:15 YFNPYNDGANYNEKFKG(CDRH2)
SEQ ID NO:16 GPYGNYAMDY(CDRH3)
抗体1IB10轻链可变区氨基酸序列为SEQ ID NO:17所示,重链可变区氨基酸序列为SEQ ID NO:19所示;
SEQ ID NO:17
DVLMTQTPLSLPVSLGDQASISCRSSQNIVCSYGNPCLEWYLQKPGQSPKLLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDLGVYYCFQSSHVPWTFGGGTELEIKR
SEQ ID NO:19
VKLQQSGPELVKPGASVKMSCRASGYTFTSYVMHWVKQKPGQGLEWIGYFNPYNDGANYNEKFKGKATLSSDKSSGTAYMDLSSLTSEDSAVYYCARGPYGNYAMDYWGQGTSVTVSSA
编码抗体1IB10的轻链可变区的核苷酸序列如SEQ ID NO:18所示,编码抗体1IB10的重链可变区的核苷酸序列如SEQ ID NO:20所示;
SEQ ID NO:18
GATGTTTTGATGACCCAGACGCCACTCTCCCTGCCTGTCAGTCTTGGAGATCAAGCCTCCATCTCTTGCAGATCTAGTCAGAACATTGTATGTAGTTATGGAAACCCCTGTTTAGAATGGTACCTGCAGAAACCAGGCCAGTCTCCAAAGCTCCTGATCTACAAAGTTTCCAACCGATTTTCTGGGGTCCCAGACAGGTTCAGTGGCAGTGGATCAGGGACAGATTTCACACTCAAGATCAGCAGAGTGGAGGCTGAGGATCTGGGAGTTTATTACTGCTTTCAAAGTTCACATGTTCCGTGGACGTTCGGTGGAGGCACCGAGCTGGAAATCAAACGG
SEQ ID NO:20
GTGAAGCTGCAGCAGTCTGGACCTGAGCTGGTAAAGCCTGGGGCTTCAGTGAAGATGTCCTGCAGGGCTTCTGGATACACATTCACTAGCTATGTTATGCACTGGGTGAAGCAGAAGCCTGGGCAGGGCCTTGAGTGGATTGGATATTTTAATCCTTACAATGACGGTGCTAACTACAATGAGAAGTTCAAAGGCAAGGCCACACTGTCTTCAGACAAATCCTCCGGCACAGCCTATATGGACCTCAGCAGCCTGACCTCTGAGGACTCTGCGGTCTATTATTGTGCGAGAGGCCCCTATGGTAACTATGCTATGGACTACTGGGGTCAAGGAACCTCAGTCACCGTCTCCTCAGCC
鼠抗MCR-1/MCR-2蛋白单克隆抗体通过系统性评价,包括对抗体亚型及效价、试剂盒灵敏度、特异性和稳定性的评价;MCR-1蛋白和MCR--2蛋白较为相似,本发明制备得到的鼠抗MCR-1/MCR-2蛋白单克隆抗体既能够特异性识别MCR-1蛋白也能够特异性识别MCR-2蛋白,并在各方面均有较佳表现,从而适合作为免疫诊断试剂用于制备体外诊断试剂盒,用于检验MCR-1蛋白和/或MCR--2蛋白。具体可以制作成胶体金免疫试剂盒、化学发光试剂盒、放射免疫试剂盒、酶联免疫试剂盒或荧光免疫试剂盒,或者制作为微流体芯片;制作的试剂盒能够检测MCR-1、MCR-2蛋白。本方案所涉及的两种抗体尤其适合搭配形成双抗体夹心法免疫胶体金试纸条,其中抗体2DG5为包被抗体,抗体1IB10为金标抗体,制得的胶体金试纸条灵敏性更高,同时,也可将抗体2DG5做为金标抗体,抗体1IB10为包被抗体。
下面通过具体实施例对本发明做出进一步说明。其中,未具体说明操作步骤的实验方法,均按照相应商品说明书进行,实施例中所用到的仪器、试剂、耗材如无特殊说明,均可从商业公司购买得到。
实施例1:鼠抗MCR-1/MCR-2蛋白单克隆抗体的制备
1.1 抗原制备
从NCBI中查找并下载mcr-1与mcr-2型基因序列,分别将重组质粒转化到大肠杆菌中进行诱导表达;纯化方法为镍柱亲和层析,菌体重悬于平衡缓冲液pH7.4中,超声至菌液澄清,高速离心,上清过膜后过镍柱,洗脱出目的蛋白,分子量和预计相符,SDS-PAGE如图1-图2所示,用BCA法定量后分装。
1.2 小鼠免疫
用纯化的MCR-1蛋白免疫6周龄左右的雌性Balb/c小鼠,进行抗体制备,按照免疫剂量分为2组,每组5只小鼠;按照抗原含量计算,第一组免疫剂量为25ug/只,第二组免疫剂量为50ug/只,首免,取适量MCR-1蛋白经生理盐水稀释至500ul,加入等量弗氏完全佐剂500ul乳化均匀,皮下多点注射免疫小鼠;两周后,取相同剂量进行二免,二免将佐剂换为弗氏不完全佐剂,并腹腔注射免疫小鼠,两周后再追加免疫一次,亦为腹腔注射免疫小鼠,7天后鼠尾采血,ELISA测定小鼠血清效价。具体步骤为:MCR-1蛋白 0.2ug/ml,100ul/孔,4℃过夜包被ELISA板,甩干,PBST洗涤3次。5%脱脂乳粉,200ul/孔,37度封闭2h。小鼠鼠尾采血,3000转/min,离心后收集血清,从1:1000开始用PBS进行倍比稀释至1:512000,备用。甩干,PBST洗涤3次,1:1000倍起加入PBS稀释的一抗,100ul/孔,37度,1h。甩干,PBST洗涤3次,加PBS 1:10000倍稀释的羊抗鼠二抗,100ul/孔,37度,45min。甩干,PBST洗涤5次,加100ulTMB/孔,37℃,显色10min,终止,读值。
1.3 细胞融合
融合前三天进行小鼠加强免疫,接种量同前次免疫,不加佐剂,腹腔注射。融合前一天准备饲养层细胞,取6-8周龄小鼠Balb/c 1只,取眼球放血后颈椎脱位致死,放于75%酒精中消毒5min,固定于盘上,在超净台中无菌剪开腹部皮肤。用无菌注射器吸取HAT选择培养液10ml注入小鼠腹腔,用酒精棉球轻揉腹部,抽回培养基。加入40ml HAT培养液中,铺入到4块96孔细胞培养板中,100μL/ 孔,37℃,5%CO2细胞培养箱中培养。融合前一周复苏骨髓瘤细胞(Sp2/0细胞),用含10%胎牛血清的PRMI-1640培养基培养,37℃,5%CO2培养箱中传代培养。将处于对数生长期的细胞收集至离心管中,细胞计数,把细胞稀释为107个/ml备用。取加强免疫3天的Balb/c小鼠,摘眼球放血制备阳性血清,脱颈椎处死,75%酒精消毒5min,在超净工作台无菌取出脾脏,在无菌平皿中冼涤数次,剥离结缔组织。将脾脏放在微孔铜网上,加入新鲜的RPMI-1640培养液,先用注射器吸取培养液由脾脏一段注入,吹下脾细胞,反复数次之后,用注射器的内塞轻轻将剩余脾脏研磨,直到无明显的红色组织块。将平皿中脾细胞悬液轻轻吹打后转移到50ml离心管中,1000r/min离心5min,收集脾细胞,计数后备用。将免疫鼠脾细胞与Sp2/0细胞按细胞数量10:1混合,加入50ml的离心管内,1000r/min离心5min,弃上清,在手心轻轻摩擦使两种细胞充分混匀,将离心管至于100mL蓝盖瓶内,蓝盖瓶内装有37℃热水,将预热好的1ml DMSO/PEG在1min内逐滴加入融合管内,先慢后快,边加边轻轻旋转离心管。然后立即加入无抗无血RPMI-1640培养液终止反应,第一分钟加1ml,第二分钟加2ml,第三分钟加3ml,第四分钟加4ml。37℃水浴5min,后800r/min离心5min,弃上清,将沉淀以HAT悬起,混匀到40ml含37℃预热的20%小牛血清的HAT选择培养液中,铺入已加有饲养细胞的96孔细胞板中,100μL/孔,将培养板放入37℃,5%CO2培养箱培养。7d后将用新鲜的HAT培养基对细胞板半换液,10天后用HT培养基全换液。将96孔板中检测阳性的细胞采用有限稀释法进行亚克隆:首先按照上述方法制备饲养层细胞,取待克隆杂交瘤细胞进行细胞计数,用HT培养基将细胞稀释至5-8个细胞/ml,加入到已铺饲养细胞的96孔细胞板中100μL/孔,每株杂交瘤细胞克隆一块96孔细胞板,37℃、5%CO2细胞培养箱中培养。约5天后数出细胞孔里的克隆数,标记,7天时并换新的培养基,待细胞铺满整个孔底的1/3~1/2时检测。经过2-3次克隆化,待96孔板所有细胞孔均为阳性时,即可进行扩大培养,定株,冻存。将检测阳性确定定株的杂交瘤细胞扩大培养并冻存。具体过程如下:将生长旺盛、状态良好的杂交瘤细胞用无抗无血DMEM轻轻从细胞瓶上吹下,1000 r/min离心5min,弃去上清。加入冻存液(含40%RPMI-1640培养液、50%胎牛血清、10%DMSO),将细胞吹散后分装到细胞冻存管中。将冻存管放入冻存盒置于-70℃冰箱中,一天后将冻存管转移入液氮中,做好记录。
1.4 腹水制备
取10-12周龄雌性 Balb/c小鼠,腹腔注射无菌液体石蜡,0.5mL/只,7d后腹腔注射培养至对数期的杂交瘤细胞,5×106个细胞/只。每天注意观察,约7-10天,待小鼠腹部出现明显隆起后,用75%酒精棉球消毒下腹部皮肤,用16号针头刺入腹腔,收集腹水。待腹水再生积聚后,再次收集。将收集的腹水3000 r/min离心10min,取中间澄清部分,用滤纸过滤后,分装,-70℃保存。
1.5 抗体纯化
用Protein-G柱子进行腹水纯化,步骤如下:取腹水2ml,10000g离心,取澄清部分,加入2ml洗涤缓冲液,混匀,柱子用20%乙醇流尽后用8mL洗涤液平衡,样本过柱子,流速为8S/滴,反复上样3次,然后用15mL洗涤缓冲液进行洗涤淀,流速为8S/滴,洗涤完毕后用10mL的洗脱缓冲液进行洗脱,洗脱完毕会用1M Tris PH=9调PH至7.4,然后用浓缩注进行浓缩,于50kd透析袋,PBS,4℃透析过夜。
实施例2:鼠抗MCR-1、MCR-2蛋白单克隆抗体的鉴定
2.1抗体亚类鉴定
按照SIGMA试剂盒说明书,以捕获ELISA的方法进行单抗的亚类鉴定,具体如下:将单抗亚类鉴定试剂1:1000稀释后,加入酶标孔中,100μL/孔,37℃孵育1h;PBST洗三次,拍干;将抗体1:1000倍稀释后加样,100 μL/孔,37℃孵育1h;PBST洗三次,拍干;HRP酶标羊抗鼠IgG二抗以1:10000稀释后加样, 100μL/孔,室温孵育30min;显色10~20min。以OD450读值明显高于其他孔所加亚类试剂为单抗所属亚类类型。抗体2DG5、1IB10的抗体亚型为IgG1。
2.2 抗体效价测定
采用间接ELISA法进行纯化后抗体效价测定,步骤如下:分别将MCR-1蛋白和MCR-2蛋白稀释至0.2ug/mL,100ul/孔,同时设立不包被对照,4℃过夜包被,甩干,PBST洗涤3次;5%脱脂乳粉,200ul/孔,37度封闭2h;甩干,PBST洗涤3次,加入从1:1000倍开始进行倍比稀释的抗体(浓度为1mg/ml),共计12个梯度,同时设立不包被对照100ul/孔, 37℃,1h。甩干,PBST洗涤3次,加 PBS 1:10000倍稀释的羊抗鼠二抗,100ul/孔,37℃,45min。甩干,PBST洗涤5次,加100ulTMB/孔,37℃,显色10min,终止,读值。纯化后抗体稀释至1mg/ml,针对MCR-1蛋白和MCR-2蛋白分别进行效价检测,效价均达到了1:1280000以上。
2.3 抗体纯度及分子量鉴定
采用SDS-PAGE法进行抗体分子量及纯度鉴定;制胶,分离胶为12%,浓缩胶为5%;制样,20ul样品+20ul buffer,混匀,煮沸3min;每孔上样20ul,同时设立蛋白预染Marker对照; 80伏30min,120伏2h;电泳完毕后,放入考马斯亮蓝溶液进行染色;脱色,去离子水煮沸脱色,每次5min,共计3次;lgG抗体重链的分子质量一般为50-75KDa,lgG抗体轻链的分子量约为25KDa,通过SDS-PAGE对纯化得到的单克隆抗体进行鉴定;如图2所示,抗体2DG5和抗体1IB10在50-75KDa和约25KDa处均各有清晰的条带。
实施例3:鼠抗MCR-1、MCR-2蛋白单克隆抗体的基因验证
RT-PCR法克隆Ig可变区基因,提取总RNA,合成单链cDNA;用Trizol法(试剂盒购自Invitrogen)提取1IB10, 2DG5杂交瘤细胞株的总RNA,用M-MLV逆转录酶(购自Invitrogen)将总RNA逆转为cDNA文库。
重链骨架区上游引物
P1:5’SAGGTGMAGCTKCASSARTCWGG3’
重链可变区下游引物
P2:5’TGGGGSTGTYGTTTTGGCTGMRGAGACRGTGA3’
轻链前导肽上游引物
P3:5’ATGGATTTTCAAGTGCAGATTTTCAG3’
轻链可变区下游引物
P4:5’GGATACAGTTGGTGCAGCATCAGCCCGTTT3’
配制PCR反应体系(50μl)如下:
cDNA:2μl;上游引物(10μM):2μl;下游引物(10μM):2μl;dNTP mixture:2μl;pfuDNA聚合酶(5U/μl):1μl;10×pfu Buffer Ⅱ:5μl;ddH2O:补足至50μl。
反应条件:95℃预变性5min;重复如下循环35次:95℃30s,58℃30s,72℃1min;最后,72℃延伸10min。
琼脂糖凝胶电泳分离并回收VL、VH片段。将回收后的VL、VH片段分别与pMD19-T(sKPCle)载体(Takara公司)进行连接,连接体系如下:
VL PCR产物/VH PCR产物各70ng,pMD19-T(sKPCle) 载体1μl,Solution I连接反应液5μl;ddH2O补足至10μl,4℃连接过夜。
连接产物转化入E.coli DH5α感受态细菌中,37℃过夜培养后,挑取单个菌落,37℃震摇2小时后进行菌液PCR鉴定,以对应抗体的cDNA为阳性对照。配制反应体系(25μl)如下:
菌液:1μl,上游引物(10μM):1μl;下游引物(10 μM) :1μl;dNTP Mixture (各2.5Mm) 2 μl;Taq DNA聚合酶 (5U/μl):0.5 μl;10×Taq Buffer (Mg2+ plus):2.5 μl;补水至25μl。反应条件同前。
选取菌PCR阳性的克隆扩大培养,用质粒提取试剂盒(Takara公司)提取阳性克隆质粒,送检测序。每个抗体的每条链至少送检5个克隆样品,至少三个样品测序结果相同为止。成功克隆得到抗体1IB10、2DG5的重链、轻链可变区序列,经比对符合典型抗体可变区序列特征。
实施例4:胶体金法制备MCR-1/MCR-2蛋白检测卡
制备双抗体夹心法免疫胶体金试纸条,制备方法为:
步骤一向胶体金溶液中边搅拌边加入0.1M K2CO3溶液,调节pH值后加入抗MCR-1单克隆抗体1IB10,搅拌后加入10%的牛血清白蛋白溶液,2%PEG20000,搅拌后低速离心取上清,再高速离心后取沉淀,用胶体金重悬液定容形成金标抗体;
步骤二将金标抗体喷于玻璃纤维素膜,烘干制成金标垫;
步骤三向鼠抗MCR-1/MCR-2蛋白单克隆抗体2DG5中加入1%的硫柳汞钠溶液,混匀后形成检测线包被液,再向羊抗鼠IgG中加入PBS和1%的硫柳汞钠溶液,混匀后形成质控线包被液,将质控线包被液和检测线包被液划在硝酸纤维素膜上,烘干后获得包被膜;
步骤四将包被膜贴在底板上,将金标垫和吸水纸搭上包被膜,层压后切割获得胶体金法MCR-1/MCR-2蛋白检测卡。
取通过上述方法制备得到的胶体金法MCR-1/MCR-2蛋白检测卡,分别取空白样、MCR-1抗原、MCR-2抗原、含有MCR-1蛋白阳性样本1和含有MCR-2蛋白阳性样本2点样于检测卡。结果如图3所示,从左到右依次为空白样、MCR-1抗原、MCR-2抗原、含有MCR-1蛋白阳性样本1和含有MCR-2蛋白阳性样本2,能够看出,空白样点样的检测卡检测结果呈阴性,MCR-1抗原、MCR-2抗原、含有MCR-1蛋白阳性样本1和含有MCR-2蛋白阳性样本2点样结果均为阳性,证明通过本方案制备得到的胶体金法MCR-1/MCR-2蛋白检测卡能够检测MCR-1蛋白或MCR-2蛋白及相应阳性样本。
以上对本发明的实施例进行了详细说明,但所述内容仅为本发明的较佳实施例,不能被认为用于限定本发明的实施范围。凡依本发明申请范围所作的均等变化与改进等,均应仍归属于本发明的专利涵盖范围之内。
序列表
<110> 天津一瑞生物科技股份有限公司
北京金山川科技股份有限公司
天津喜诺生物医药有限公司
<120> 一种鼠抗MCR-1/MCR-2蛋白杂交瘤细胞株,单克隆抗体及应用
<130> 2021
<160> 20
<170> SIPOSequenceListing 1.0
<210> 1
<211> 11
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 1
Arg Ala Ser Gln Asp Ile Asn Asn Tyr Leu Asn
1 5 10
<210> 2
<211> 7
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 2
Tyr Thr Ser Arg Leu His Ser
1 5
<210> 3
<211> 10
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 3
Gln Gln Gly Lys Thr Ile His Pro Trp Thr
1 5 10
<210> 4
<211> 11
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 4
Gly Tyr Ser Ile Thr Ser Asp Tyr Ala Trp Asn
1 5 10
<210> 5
<211> 16
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 5
Gln Ile Ser Asp Ser Ala Val Thr Thr Tyr Asn Pro Ser Leu Lys Ser
1 5 10 15
<210> 6
<211> 11
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 6
Arg Asn Phe Tyr Gly Tyr Asn Phe Phe Asp Tyr
1 5 10
<210> 7
<211> 110
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 7
Asp Ile Gln Met Thr Gln Thr Thr Ser Ser Leu Ser Ala Ser Leu Gly
1 5 10 15
Asp Arg Val Thr Ile Asn Cys Arg Ala Ser Gln Asp Ile Asn Asn Tyr
20 25 30
Leu Asn Trp Tyr Gln Gln Lys Pro Asp Gly Thr Val Lys Leu Leu Ile
35 40 45
Tyr Tyr Thr Ser Arg Leu His Ser Gly Val Pro Ser Arg Phe Ser Gly
50 55 60
Ser Gly Ser Arg Thr Asp Tyr Ser Leu Thr Ile Ser Asn Leu Glu Arg
65 70 75 80
Glu Asp Ile Ala Thr Tyr Phe Cys Gln Gln Gly Lys Thr Ile His Pro
85 90 95
Trp Thr Phe Gly Gly Gly Thr Lys Leu Asp Ile Lys Arg Ala
100 105 110
<210> 8
<211> 330
<212> DNA
<213> 人工序列(Artificial Sequence)
<400> 8
gatatccaga tgacacagac tacatcctcc ctgtctgcct ctctgggaga cagagtcacc 60
atcaattgca gggcaagtca ggacattaac aattatttaa actggtatca gcagaaacca 120
gatggaactg ttaaactcct gatctactac acttcaagat tacattcagg agtcccatca 180
aggttcagcg gcagtgggtc tagaacagat tattctctca ccattagcaa cctggaacga 240
gaagatattg ccacttactt ttgccaacag ggtaaaacga ttcatccgtg gacgttcggt 300
ggaggcacca agctggacat caaacgggct 330
<210> 9
<211> 121
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 9
Val Lys Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Gln Ser
1 5 10 15
Leu Ser Leu Thr Cys Thr Val Thr Gly Tyr Ser Ile Thr Ser Asp Tyr
20 25 30
Ala Trp Asn Trp Ile Arg Gln Phe Pro Gly Asn Lys Leu Glu Trp Met
35 40 45
Gly Gln Ile Ser Asp Ser Ala Val Thr Thr Tyr Asn Pro Ser Leu Lys
50 55 60
Ser Arg Ile Ser Ile Asn Arg Asp Thr Ser Lys Asn Gln Phe Phe Leu
65 70 75 80
Gln Leu Asn Ser Val Thr Pro Glu Asp Thr Ala Thr Tyr Tyr Cys Ala
85 90 95
Arg Arg Asn Phe Tyr Gly Tyr Asn Phe Phe Asp Tyr Trp Gly Arg Gly
100 105 110
Thr Ser Leu Thr Val Ser Ser Ala Lys
115 120
<210> 10
<211> 363
<212> DNA
<213> 人工序列(Artificial Sequence)
<400> 10
gtgaagctgc aggagtcagg acctggcctg gtgaaacctt ctcagtctct gtccctcacc 60
tgcactgtca ctggctactc aatcaccagt gattatgcct ggaactggat ccggcagttt 120
ccaggaaaca aactggagtg gatgggccag ataagcgaca gtgctgtcac tacctacaac 180
ccatctctca aaagtcgaat ctctatcaat cgagacacat ccaagaacca gttcttcctg 240
cagttgaatt ctgtgactcc tgaggacaca gccacatatt actgtgcaag aaggaacttc 300
tacgggtaca atttttttga ctactggggc cgaggcacct ctctcactgt ctcttcagcc 360
aaa 363
<210> 11
<211> 16
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 11
Arg Ser Ser Gln Asn Ile Val Cys Ser Tyr Gly Asn Pro Cys Leu Glu
1 5 10 15
<210> 12
<211> 7
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 12
Lys Val Ser Asn Arg Phe Ser
1 5
<210> 13
<211> 9
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 13
Phe Gln Ser Ser His Val Pro Trp Thr
1 5
<210> 14
<211> 10
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 14
Gly Tyr Thr Phe Thr Ser Tyr Val Met His
1 5 10
<210> 15
<211> 17
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 15
Tyr Phe Asn Pro Tyr Asn Asp Gly Ala Asn Tyr Asn Glu Lys Phe Lys
1 5 10 15
Gly
<210> 16
<211> 10
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 16
Gly Pro Tyr Gly Asn Tyr Ala Met Asp Tyr
1 5 10
<210> 17
<211> 113
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 17
Asp Val Leu Met Thr Gln Thr Pro Leu Ser Leu Pro Val Ser Leu Gly
1 5 10 15
Asp Gln Ala Ser Ile Ser Cys Arg Ser Ser Gln Asn Ile Val Cys Ser
20 25 30
Tyr Gly Asn Pro Cys Leu Glu Trp Tyr Leu Gln Lys Pro Gly Gln Ser
35 40 45
Pro Lys Leu Leu Ile Tyr Lys Val Ser Asn Arg Phe Ser Gly Val Pro
50 55 60
Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile
65 70 75 80
Ser Arg Val Glu Ala Glu Asp Leu Gly Val Tyr Tyr Cys Phe Gln Ser
85 90 95
Ser His Val Pro Trp Thr Phe Gly Gly Gly Thr Glu Leu Glu Ile Lys
100 105 110
Arg
<210> 18
<211> 339
<212> DNA
<213> 人工序列(Artificial Sequence)
<400> 18
gatgttttga tgacccagac gccactctcc ctgcctgtca gtcttggaga tcaagcctcc 60
atctcttgca gatctagtca gaacattgta tgtagttatg gaaacccctg tttagaatgg 120
tacctgcaga aaccaggcca gtctccaaag ctcctgatct acaaagtttc caaccgattt 180
tctggggtcc cagacaggtt cagtggcagt ggatcaggga cagatttcac actcaagatc 240
agcagagtgg aggctgagga tctgggagtt tattactgct ttcaaagttc acatgttccg 300
tggacgttcg gtggaggcac cgagctggaa atcaaacgg 339
<210> 19
<211> 119
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 19
Val Lys Leu Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Ala Ser
1 5 10 15
Val Lys Met Ser Cys Arg Ala Ser Gly Tyr Thr Phe Thr Ser Tyr Val
20 25 30
Met His Trp Val Lys Gln Lys Pro Gly Gln Gly Leu Glu Trp Ile Gly
35 40 45
Tyr Phe Asn Pro Tyr Asn Asp Gly Ala Asn Tyr Asn Glu Lys Phe Lys
50 55 60
Gly Lys Ala Thr Leu Ser Ser Asp Lys Ser Ser Gly Thr Ala Tyr Met
65 70 75 80
Asp Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys Ala
85 90 95
Arg Gly Pro Tyr Gly Asn Tyr Ala Met Asp Tyr Trp Gly Gln Gly Thr
100 105 110
Ser Val Thr Val Ser Ser Ala
115
<210> 20
<211> 357
<212> DNA
<213> 人工序列(Artificial Sequence)
<400> 20
gtgaagctgc agcagtctgg acctgagctg gtaaagcctg gggcttcagt gaagatgtcc 60
tgcagggctt ctggatacac attcactagc tatgttatgc actgggtgaa gcagaagcct 120
gggcagggcc ttgagtggat tggatatttt aatccttaca atgacggtgc taactacaat 180
gagaagttca aaggcaaggc cacactgtct tcagacaaat cctccggcac agcctatatg 240
gacctcagca gcctgacctc tgaggactct gcggtctatt attgtgcgag aggcccctat 300
ggtaactatg ctatggacta ctggggtcaa ggaacctcag tcaccgtctc ctcagcc 357
Claims (9)
1.鼠抗MCR-1/MCR-2蛋白杂交瘤细胞株,其特征在于:命名为2DG5,保藏编号为CGMCCNo.23034;或者命名为1IB10,保藏编号为CGMCC No.23032。
2.鼠抗MCR-1/MCR-2蛋白抗体,其特征在于:抗体2DG5,包括轻链可变区和重链可变区,轻链可变区包括如SEQ ID NO:1所示的CDRL1、SEQ ID NO:2所示的CDRL2和SEQ ID NO:3所示的CDRL3,重链可变区包括如SEQ ID NO:4所示的CDRH1、SEQ ID NO:5所示的CDRH2和SEQID NO:6所示的CDRH3;
或者,
抗体1IB10,轻链可变区包括如SEQ ID NO:11所示的CDRL1、SEQ ID NO:12所示的CDRL2和SEQ ID NO:13所示的CDRL3,重链可变区包括如SEQ ID NO:14所示的CDRH1、SEQ ID NO:15所示的CDRH2和SEQ ID NO:16所示的CDRH3。
3.根据权利要求2所述的鼠抗MCR-1/MCR-2蛋白抗体,其特征在于:抗体2DG5轻链可变区氨基酸序列为SEQ ID NO:7所示,重链可变区氨基酸序列为SEQ ID NO:9所示;
或者,
抗体1IB10轻链可变区氨基酸序列为SEQ ID NO:17所示,重链可变区氨基酸序列为SEQID NO:19所示。
4.根据权利要求2或3所述的鼠抗MCR-1/MCR-2蛋白抗体,其特征在于:抗体2DG5由保藏编号为CGMCC No.23034的鼠抗MCR-1/MCR-2蛋白杂交瘤细胞株产生;
或者,
抗体1IB10由保藏编号为CGMCC No.23032的鼠抗MCR-1/MCR-2蛋白杂交瘤细胞株产生。
5.一种核酸分子,其特征在于:包含编码权利要求2或3所述的鼠抗MCR-1/MCR-2蛋白抗体的核苷酸。
6.根据权利要求5所述的核酸分子,其特征在于:所述核酸分子编码抗体2DG5的轻链可变区的核苷酸序列如SEQ ID NO:8所示,所述核酸分子编码抗体2DG5的重链可变区的核苷酸序列如SEQ ID NO:10所示;
或者,
所述核酸分子编码抗体1IB10的轻链可变区的核苷酸序列如SEQ ID NO:18所示,所述核酸分子编码抗体1IB10的重链可变区的核苷酸序列如SEQ ID NO:20所示。
7.权利要求2-4中任一所述的鼠抗MCR-1/MCR-2蛋白抗体在制备检测MCR-1或MCR-2蛋白试剂中的应用。
8.根据权利要求7所述的鼠抗MCR-1/MCR-2蛋白抗体在制备检测MCR-1或MCR-2蛋白试剂中的应用,其特征在于:将鼠抗MCR-1/MCR-2蛋白抗体用于制备体外诊断试剂盒或微流体芯片,所述体外诊断试剂盒为胶体金免疫试剂盒、化学发光试剂盒、放射免疫试剂盒、酶联免疫试剂盒或荧光免疫试剂盒。
9.根据权利要求7所述的鼠抗MCR-1/MCR-2蛋白抗体在制备检测MCR-1或MCR-2蛋白试剂中的应用,其特征在于:制备双抗体夹心法免疫胶体金试纸条,抗体2DG5为包被抗体,抗体1IB10为金标抗体;
或者,抗体1IB10为包被抗体,抗体2DG5为金标抗体。
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210189230.1A CN114250203B (zh) | 2022-03-01 | 2022-03-01 | 一种鼠抗mcr-1/mcr-2蛋白杂交瘤细胞株,单克隆抗体及应用 |
EP22871086.9A EP4265717A4 (en) | 2022-03-01 | 2022-12-23 | MOUSE ANTI-MCR-1/MCR-2 PROTEIN HYBRIDOMA CELL STRAIN, MONOCLONAL ANTIBODY AND USE |
PCT/CN2022/141244 WO2023165230A1 (zh) | 2022-03-01 | 2022-12-23 | 一种鼠抗mcr-1/mcr-2蛋白杂交瘤细胞株,单克隆抗体及应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210189230.1A CN114250203B (zh) | 2022-03-01 | 2022-03-01 | 一种鼠抗mcr-1/mcr-2蛋白杂交瘤细胞株,单克隆抗体及应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN114250203A CN114250203A (zh) | 2022-03-29 |
CN114250203B true CN114250203B (zh) | 2022-05-31 |
Family
ID=80800082
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202210189230.1A Active CN114250203B (zh) | 2022-03-01 | 2022-03-01 | 一种鼠抗mcr-1/mcr-2蛋白杂交瘤细胞株,单克隆抗体及应用 |
Country Status (3)
Country | Link |
---|---|
EP (1) | EP4265717A4 (zh) |
CN (1) | CN114250203B (zh) |
WO (1) | WO2023165230A1 (zh) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114250203B (zh) * | 2022-03-01 | 2022-05-31 | 天津一瑞生物科技股份有限公司 | 一种鼠抗mcr-1/mcr-2蛋白杂交瘤细胞株,单克隆抗体及应用 |
CN114807054B (zh) * | 2022-06-24 | 2022-09-13 | 北京索莱宝科技有限公司 | 小鼠抗人IgG单抗杂交瘤细胞株、抗体、抗体组合物及试剂盒 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113416710A (zh) * | 2021-08-25 | 2021-09-21 | 天津一瑞生物科技股份有限公司 | 一种鼠抗mcr-1蛋白杂交瘤细胞株,单克隆抗体及应用 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11161896B2 (en) * | 2018-04-20 | 2021-11-02 | The United States Of America, As Represented By The Secretary Of Agriculture | Antibodies for detection of colistin-resistance |
CN111487417B (zh) * | 2020-03-16 | 2024-01-23 | 北京维德维康生物技术有限公司 | Mcr-1耐药蛋白双抗夹心elisa检测试剂盒及检测方法 |
CN114250203B (zh) * | 2022-03-01 | 2022-05-31 | 天津一瑞生物科技股份有限公司 | 一种鼠抗mcr-1/mcr-2蛋白杂交瘤细胞株,单克隆抗体及应用 |
CN114317455B (zh) * | 2022-03-02 | 2022-05-31 | 天津一瑞生物科技股份有限公司 | 鼠抗mcr-1蛋白杂交瘤细胞株,单克隆抗体及应用 |
-
2022
- 2022-03-01 CN CN202210189230.1A patent/CN114250203B/zh active Active
- 2022-12-23 EP EP22871086.9A patent/EP4265717A4/en active Pending
- 2022-12-23 WO PCT/CN2022/141244 patent/WO2023165230A1/zh unknown
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113416710A (zh) * | 2021-08-25 | 2021-09-21 | 天津一瑞生物科技股份有限公司 | 一种鼠抗mcr-1蛋白杂交瘤细胞株,单克隆抗体及应用 |
Non-Patent Citations (2)
Title |
---|
Identification of Functional Interactome of Colistin Resistance Protein MCR-1 in Escherichia coli;Hui Li et al.;《Frontiers in Microbiology》;20210125;第1-9页 * |
利用宏基因组方法对四川地区规模化养猪场粪便中耐药基因污染特征的研究;潘梦等;《兽医科学》;20211231;第58-64页 * |
Also Published As
Publication number | Publication date |
---|---|
EP4265717A1 (en) | 2023-10-25 |
EP4265717A4 (en) | 2024-04-17 |
CN114250203A (zh) | 2022-03-29 |
WO2023165230A1 (zh) | 2023-09-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN112500489B (zh) | 一种抗oxa-23型碳青霉烯酶杂交瘤细胞株,单克隆抗体及应用 | |
CN112501131B (zh) | 抗imp型碳青霉烯酶杂交瘤细胞株,单克隆抗体及应用 | |
CN113416710B (zh) | 一种鼠抗mcr-1蛋白杂交瘤细胞株,单克隆抗体及应用 | |
CN112980803B (zh) | 抗vim型碳青霉烯酶杂交瘤细胞株,单克隆抗体及应用 | |
CN114250203B (zh) | 一种鼠抗mcr-1/mcr-2蛋白杂交瘤细胞株,单克隆抗体及应用 | |
CN112980804B (zh) | 一种抗kpc型碳青霉烯酶杂交瘤细胞株,单克隆抗体及应用 | |
CN109438576B (zh) | 一种抗人cd47单克隆抗体的制备及其应用 | |
CN114317455B (zh) | 鼠抗mcr-1蛋白杂交瘤细胞株,单克隆抗体及应用 | |
CN114317454B (zh) | 一种鼠抗oxa-48型碳青霉烯酶杂交瘤细胞株,单克隆抗体及应用 | |
EP4261278A1 (en) | Mouse anti-ndm carbapenemase hybridoma cell strain, monoclonal antibody and use | |
CN116574182B (zh) | 一种抗人Ki-67抗体及其制备方法和用途 | |
CN113527474A (zh) | 一种抗新冠病毒n蛋白的单克隆抗体及其应用 | |
CN109880805B (zh) | 抗隐球菌荚膜多糖单克隆抗体及其杂交瘤细胞株制备与应用 | |
CN116462758B (zh) | 抗人ptprz1单克隆抗体及其在细胞流式中的应用 | |
CN116769040B (zh) | 鼠抗gdh杂交瘤细胞株,单克隆抗体及应用 | |
CN117024595B (zh) | 抗人st2的单克隆抗体及其应用 | |
CN116769023B (zh) | 鼠抗马尔尼菲篮状菌甘露聚糖蛋白杂交瘤细胞株,单克隆抗体及应用 | |
CN116063535B (zh) | 一种抗体或其抗原结合片段及其制备方法和应用 | |
CN115304670A (zh) | 一种猫冠状病毒核衣壳蛋白的鼠源单克隆抗体及其编码基因和应用 | |
CN108484762B (zh) | 一种甲胎蛋白检测用抗体IgM及应用 | |
CN117866909A (zh) | 一种杂交瘤细胞株及其在生产cd74单克隆抗体上的应用 | |
CN117801102A (zh) | 一种猫血清淀粉样蛋白a单克隆抗体、检测试纸条及应用 | |
CN115948346A (zh) | 一株能稳定分泌抗芋螺毒素μ-KIIIA-CTX单克隆抗体的杂交瘤细胞株 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |